Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis

• Principais autores: Christophe Sapin (Autor), Ann Hartry (Autor), Siddhesh A Kamat (Autor), Maud Beillat (Autor), Ross A Baker (Autor), Anna Eramo (Autor)
• Formato: Livro
• Publicado em: BioExcel Publishing Ltd, 2016-09-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Schizophrenia presents a substantial clinical and economic burden to the health-care system. In QUAlity of LIfe with AbiliFY Maintena (QUALIFY), a randomized head-to-head study of aripiprazole once-monthly 400 mg (AOM 400) compared with paliperidone palmitate (PP; 78-234 mg/mo), AOM 400 demonstrated...